So, according to the EGIL classification, there were 4 (5.4%) cases of Pro-B-ALL or EGIL B-1 subtype [(A positive reaction for any two of CD19, CD22 (membrane and cytoplasm) and CD79a) without further differentiation markers] and 71 (94.6%) cases of CD10 positive B-ALL (EGIL B-2) subtype (Chiaretti et al., 2014). This evidence concerns the gene CD79A and acute lymphoblastic leukemia.